Alpha 1-Antitrypsin Deficiency - 59 Studies Found
| Active, not recruiting |
: Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency : Alpha 1-Antitrypsin Deficiency : 2006-09-14 : Genetic: rAAV2-CB-hAAT Gene Vector Participants will attend a 5-day inpatient visit, during which they w |
| Completed |
: Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) :
|
| Completed |
: Pharmacokinetic Study of ARALAST (Human Alpha1- PI) : Alpha 1-Antitrypsin Deficiency : 2005-10-19 :
|
| Completed |
: Phase II, Safety and ELF Study of "Kamada-API for Inhalation" : Alpha-1 Antitrypsin Deficiency : 2013-11-24 :
|
| Withdrawn |
: Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels : Alpha-1 Antitrypsin Deficiency : 2016-09-09 : Drug: ARC-AAT Injection RNA interference (RNAi)-based, liver-targeted therapeutic |
| Completed |
: Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency :
|
| Completed |
: Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema :
: 2008-06-18 |
| Completed |
: 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? : Alpha 1-Antitrypsin Deficiency : 2003-08-26 : Drug: 4-PBA During the first 3 days of this phase baseline serum AAT levels will be determined. The part |
| Completed |
: Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) : Alpha 1-Antitrypsin Deficiency : 2005-09-12 :
|
| Completed |
: Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) : Alpha 1-Antitrypsin Deficiency : 2006-11-03 : Biological: Alpha1-Proteinase Inhibitor 60 mg/kg, weekly, intravenous infusion |